Superluminal Medicines Secures $60 Million to Advance Obesity Program

The financing was led by BVF Partners, L.P., with support from new investors Deep Track Capital and Perceptive Advisors. Existing backers, including RA Capital Management, Insight Partners, NVIDIA, Eli Lilly and Company, and Catalio Capital Management, also participated in the round. This capital infusion marks a pivot for the company as it shifts from a discovery-focused entity toward becoming a clinical-stage organization.

At the center of the company’s pipeline is a selective, biased MC4R agonist designed to treat rare genetic forms of obesity and hypothalamic obesity. By focusing on the MC4R pathway, Superluminal aims to regulate energy homeostasis and appetite while reducing side effects through precise signaling activation. Preclinical data for the candidate indicates high selectivity, providing a foundation for potential future applications in conditions like Prader-Willi syndrome or as a combination therapy alongside GLP-1 treatments.

Superluminal’s R&D engine integrates Agentic Cryo-EM capabilities with proprietary machine learning to map complex G protein-coupled receptor (GPCR) targets. This technological stack allows the company to rapidly generate empirical structural data and design small-molecule candidates. Beyond its internal pipeline, the firm maintains strategic collaborations, most notably with Eli Lilly and Company, to target GPCRs associated with cardiometabolic diseases. Cony D'Cruz, CEO of Superluminal, noted that the support from this investor syndicate validates the company's ability to translate complex structural biology into potential clinical breakthroughs for patients with significant unmet medical needs.